Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32,253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Denfivontinib activates effector T-cells through NLRP3-inflammasome, yielding potent anticancer effects by combination with pembrolizumab.
Kim DK, Synn CB, Lee W, Jo HN, Lee CY, Lee S, Hwang JY, Kim Y, Kang SS, Baek S, Na K, Yang SM, Kim MH, Han H, Han YJ, Kim JH, Park SY, Park YJ, Lee GT, Choi SJ, Sohn JO, Ye SK, Lee JB, Lim SM, Hong MH, Pyo KH, Cho BC. Kim DK, et al. Among authors: kim mh, kim y, kim jh. Mol Cancer Ther. 2024 Dec 5. doi: 10.1158/1535-7163.MCT-24-0501. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39632711
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.
Lim SM, Kang SS, Kim DK, Lee SH, Synn CB, Baek S, Yang SM, Han YJ, Kim MH, Han H, Na K, Kim YT, Yun MR, Kim JH, Byeon Y, Kim YS, Lee JB, Hong MH, Curtin JC, Patel B, Bergiers I, Pyo KH, Cho BC. Lim SM, et al. Among authors: kim dk, kim ys, kim mh, kim yt, kim jh. Cancer Res Commun. 2024 Jul 1;4(7):1748-1764. doi: 10.1158/2767-9764.CRC-24-0107. Cancer Res Commun. 2024. PMID: 38916448 Free PMC article.
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC. Yun J, et al. Among authors: kim sy, kim hr, kim jh. Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15. Cancer Discov. 2020. PMID: 32414908 Clinical Trial.
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.
Ahn BC, So JW, Synn CB, Kim TH, Kim JH, Byeon Y, Kim YS, Heo SG, Yang SD, Yun MR, Lim S, Choi SJ, Lee W, Kim DK, Lee EJ, Lee S, Lee DJ, Kim CG, Lim SM, Hong MH, Cho BC, Pyo KH, Kim HR. Ahn BC, et al. Among authors: kim th, kim cg, kim dk, kim ys, kim hr, kim jh. Eur J Cancer. 2021 Aug;153:179-189. doi: 10.1016/j.ejca.2021.05.019. Epub 2021 Jun 26. Eur J Cancer. 2021. PMID: 34182269
Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor.
Synn CB, Kim DK, Kim JH, Byeon Y, Kim YS, Yun MR, Lee JM, Lee W, Lee EJ, Lee S, Lee YW, Lee DJ, Kim HW, Kim CG, Hong MH, Park JD, Lim SM, Pyo KH. Synn CB, et al. Among authors: kim hw, kim cg, kim dk, kim ys, kim jh. Yonsei Med J. 2022 Jan;63(1):42-55. doi: 10.3349/ymj.2022.63.1.42. Yonsei Med J. 2022. PMID: 34913283 Free PMC article.
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.
Lee W, Kim DK, Synn CB, Lee HK, Park S, Jung DS, Choi Y, Kim JH, Byeon Y, Kim YS, Lee S, Lee S, Joo Y, Lee EJ, Yun MR, Heo SG, Yang W, Jung JE, Kim EK, Park J, Park JD, Lee DJ, Kim HW, Lim SM, Hong MH, Ahn BC, Lee JB, Pyo KH. Lee W, et al. Among authors: kim hw, kim ek, kim dk, kim ys, kim jh. Front Oncol. 2022 Mar 9;12:821391. doi: 10.3389/fonc.2022.821391. eCollection 2022. Front Oncol. 2022. PMID: 35356198 Free PMC article.
YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment.
Kim DK, Synn CB, Yang SM, Kang S, Baek S, Oh SW, Lee GJ, Kang HW, Lee YS, Park JS, Kim JH, Byeon Y, Kim YS, Lee DJ, Kim HW, Park JD, Lee SS, Lee JY, Lee JB, Kim CG, Hong MH, Lim SM, Kim HR, Pyo KH, Cho BC. Kim DK, et al. Among authors: kim hw, kim cg, kim ys, kim hr, kim jh. Front Chem. 2022 Dec 5;10:998013. doi: 10.3389/fchem.2022.998013. eCollection 2022. Front Chem. 2022. PMID: 36545214 Free PMC article.
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
Na K, Lee S, Kim DK, Kim YS, Hwang JY, Kang SS, Baek S, Lee CY, Yang SM, Han YJ, Kim MH, Han H, Kim Y, Kim JH, Jeon S, Byeon Y, Lee JB, Lim SM, Hong MH, Pyo KH, Cho BC. Na K, et al. Among authors: kim dk, kim ys, kim mh, kim y, kim jh. Front Immunol. 2024 Mar 7;15:1336246. doi: 10.3389/fimmu.2024.1336246. eCollection 2024. Front Immunol. 2024. PMID: 38515751 Free PMC article.
32,253 results
You have reached the last available page of results. Please see the User Guide for more information.